siRNA and isRNA: two edges of one sword - PubMed

Review

siRNA and isRNA: two edges of one sword

Martin Schlee et al. Mol Ther. 2006 Oct.

Free article

Abstract

RNA interference mediated by small interfering RNAs (siRNA) has emerged as a powerful tool to target specific knockdown of gene expression in cell culture. siRNA is now the gold standard technique to study gene function, and expectations for the development of new target-specific drugs are high. In addition to the gene-silencing activity of siRNA, a number of recent studies have pointed to immunological effects of siRNAs, including the induction of proinflammatory cytokines and type I interferon. There is good evidence that gene silencing and immunostimulation are two independent functional characteristics of RNA oligonucleotides. Immunorecognition of RNA depends on certain molecular features such as length, double- versus single-strand configuration, sequence motifs, and nucleoside modifications such as triphosphate residues. RNA-sensing immunoreceptors include three members of the Toll-like receptor (TLR) family (TLR3, TLR7, TLR8) and cytosolic RNA-binding proteins like PKR and the helicases RIG-I and Mda5. Detection of RNA molecules occurs during viral infection and triggers antiviral innate defense mechanisms including the induction of type I interferons (IFN-alpha, IFN-beta) and downregulation of gene expression. Type I interferon induction by synthetic siRNAs requires TLR7 and is sequence dependent, similar to the detection of CpG motifs in DNA by TLR9. Identification of the exact molecular mechanisms of immunorecognition of RNA will allow the development of methods to avoid immunostimulation of siRNA and the design of potent immunostimulatory RNA (isRNA) oligonucleotides, depending on the aim. Furthermore, the combination of both gene-silencing and immunostimulation in one RNA molecule may lead to novel drugs that use both functional activities of RNA as two edges of one sword for effective treatment of viral infection and cancer.

Similar articles

• Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

  Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G. Hornung V, et al. Nat Med. 2005 Mar;11(3):263-70. doi: 10.1038/nm1191. Epub 2005 Feb 20. Nat Med. 2005. PMID: 15723075

• Astrocytes are very sensitive to develop innate immune responses to lipid-carried short interfering RNA.

  Gorina R, Santalucia T, Petegnief V, Ejarque-Ortiz A, Saura J, Planas AM. Gorina R, et al. Glia. 2009 Jan 1;57(1):93-107. doi: 10.1002/glia.20738. Glia. 2009. PMID: 18709661

• Signal regulatory protein alpha negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction.

  Dong LW, Kong XN, Yan HX, Yu LX, Chen L, Yang W, Liu Q, Huang DD, Wu MC, Wang HY. Dong LW, et al. Mol Immunol. 2008 Jun;45(11):3025-35. doi: 10.1016/j.molimm.2008.03.012. Epub 2008 May 8. Mol Immunol. 2008. PMID: 18471880

• Deciphering the code of innate immunity recognition of siRNAs.

  Sioud M. Sioud M. Methods Mol Biol. 2009;487:41-59. doi: 10.1007/978-1-60327-547-7_2. Methods Mol Biol. 2009. PMID: 19301641 Review.

• Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing.

  Seya T, Matsumoto M, Ebihara T, Oshiumi H. Seya T, et al. Immunol Rev. 2009 Jan;227(1):44-53. doi: 10.1111/j.1600-065X.2008.00723.x. Immunol Rev. 2009. PMID: 19120474 Review.

Cited by

• Master sensors of pathogenic RNA - RIG-I like receptors.

  Schlee M. Schlee M. Immunobiology. 2013 Nov;218(11):1322-35. doi: 10.1016/j.imbio.2013.06.007. Epub 2013 Jul 1. Immunobiology. 2013. PMID: 23896194 Free PMC article. Review.

• siRNA and targeted delivery systems in breast cancer therapy.

  Mirzaei S, Paskeh MDA, Entezari M, Bidooki SH, Ghaleh VJ, Rezaei S, Hejazi ES, Kakavand A, Behroozaghdam M, Movafagh A, Taheriazam A, Hashemi M, Samarghandian S. Mirzaei S, et al. Clin Transl Oncol. 2023 May;25(5):1167-1188. doi: 10.1007/s12094-022-03043-y. Epub 2022 Dec 23. Clin Transl Oncol. 2023. PMID: 36562927 Review.

• Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.

  Nguyen DN, Mahon KP, Chikh G, Kim P, Chung H, Vicari AP, Love KT, Goldberg M, Chen S, Krieg AM, Chen J, Langer R, Anderson DG. Nguyen DN, et al. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):E797-803. doi: 10.1073/pnas.1121423109. Epub 2012 Mar 15. Proc Natl Acad Sci U S A. 2012. PMID: 22421433 Free PMC article.

• Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems.

  Parameswaran P, Sklan E, Wilkins C, Burgon T, Samuel MA, Lu R, Ansel KM, Heissmeyer V, Einav S, Jackson W, Doukas T, Paranjape S, Polacek C, dos Santos FB, Jalili R, Babrzadeh F, Gharizadeh B, Grimm D, Kay M, Koike S, Sarnow P, Ronaghi M, Ding SW, Harris E, Chow M, Diamond MS, Kirkegaard K, Glenn JS, Fire AZ. Parameswaran P, et al. PLoS Pathog. 2010 Feb 12;6(2):e1000764. doi: 10.1371/journal.ppat.1000764. PLoS Pathog. 2010. PMID: 20169186 Free PMC article.

• Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.

  Jackson AL, Linsley PS. Jackson AL, et al. Nat Rev Drug Discov. 2010 Jan;9(1):57-67. doi: 10.1038/nrd3010. Nat Rev Drug Discov. 2010. PMID: 20043028 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal